Dactinomycin

Evidence Level: L5

Predicted Indications: 4

Dactinomycin

Pharmacist Assessment Report

Dactinomycin: transcription-inhibiting cytotoxic antibiotic → relapsing-remitting multiple sclerosis

One-Sentence Summary

Dactinomycin is a cytotoxic antibiotic that blocks RNA synthesis by binding to DNA, and it is marketed in India as an injectable. The TxGNN model predicts it may be effective for relapsing-remitting multiple sclerosis. There are no clinical trials and no publications on this disease, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	relapsing-remitting multiple sclerosis
TxGNN Prediction Score	0.9958
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (6 of 6) – CDSCO approval status is not included in this data
Number of Listed Products	6 (valid: 6)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available in the data compiled for this report. Dactinomycin is known as a cytotoxic transcription inhibitor: it intercalates into DNA and blocks RNA polymerase. It also causes marked bone marrow suppression.

In theory, broad suppression of dividing cells could dampen autoreactive lymphocytes, which drive multiple sclerosis. However, the data compiled for this report support no mechanistic link between dactinomycin and this disease. Its toxicity profile makes it an unlikely choice compared with established multiple sclerosis therapies. The high score of 0.9958 is a model output only, and it is not backed by any trial or publication.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
223232	Tinowel 0.5mg Injection	vial of 1 Injection	Not recorded
65406	Dactinoget 0.5mg Injection	vial of 1 Powder for Injection	Not recorded
3963	Actinocin 0.5mg Injection	vial of 1 Injection	Not recorded
43141	Cosmegen 0.5mg Injection	vial of 1 ml Injection	Not recorded
67103	Dacmozen 0.5mg Injection	vial of 2 ml Injection	Not recorded

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (antitumour antibiotic, transcription inhibitor)
Myelosuppression Risk	High (substantial myelosuppressive toxicity)
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC with differential, liver and renal function
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Conditions of concern with this drug (from drug-disease relationship data, not label text): liver disease, gallbladder disease, thrombocytopenia, neutropenia, agranulocytosis, leukopenia, anemia (including macrocytic anemia), aplastic anemia, varicella zoster infection, herpes zoster, hepatic vein thrombosis and Budd-Chiari syndrome.
Drug Interactions: 164 interactions were found. Major ones include deferiprone and samarium (153Sm) lexidronam. Moderate ones include palifermin, strontium chloride Sr-89, fostamatinib, mercaptopurine, roflumilast and chloramphenicol.

Conclusion and Next Steps

Decision: Hold

Rationale: No trials or publications study this drug in relapsing-remitting multiple sclerosis, and no mechanistic link is supported. Its marked myelosuppressive toxicity makes a favourable benefit-risk balance implausible against established therapies.

To proceed, the following is needed:

Mechanism-of-action data and a plausible immunological rationale
Preclinical studies in multiple sclerosis models
Package insert warnings and contraindications from the India product labels
A benefit-risk assessment against current disease-modifying therapies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.